How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,878 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Spongiotic Trachyonychia Treated with Topical Corticosteroids Using the Paper Tape Occlusion Method (PubMed)

Spongiotic Trachyonychia Treated with Topical Corticosteroids Using the Paper Tape Occlusion Method 27843923 2018 11 13 2296-9195 2 1-2 2016 Sep Skin appendage disorders Skin Appendage Disord Spongiotic Trachyonychia Treated with Topical Corticosteroids Using the Paper Tape Occlusion Method. 49-51 Sakiyama Tomo T Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Chaya Ayaka A Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Shimizu Tomoko T (...) Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Ebihara Tamotsu T Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Saito Masataka M Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. eng Editorial 2016 05 21 Switzerland Skin Appendage Disord 101670617 2296-9160 Nail matrix Paper tape occlusion method Spongiosis Topical corticosteroids Trachyonychia 2016 02 08 2016 04 22 2016 11 16 6 0 2016 11 16 6 0 2016 11 16 6 1 ppublish

Full Text available with Trip Pro

2016 Skin appendage disorders

142. Topical Corticosteroid Misuse: The Scenario in Patients Attending a Tertiary Care Hospital in New Delhi (PubMed)

Topical Corticosteroid Misuse: The Scenario in Patients Attending a Tertiary Care Hospital in New Delhi Irrational use of Topical Corticosteroid (TC) is quite common in India due to unrestricted availability and use of TC not only by general public but also by physicians and chemists due to quick relief of symptoms in different dermatological conditions.The present study was conducted to evaluate and analyse the prevalence of misuse of TC and the causes behind misuse of TC among patients

Full Text available with Trip Pro

2016 Journal of clinical and diagnostic research : JCDR

143. Proliferative and necrotizing otitis externa in a kitten: successful treatment with intralesional and topical corticosteroid therapy (PubMed)

Proliferative and necrotizing otitis externa in a kitten: successful treatment with intralesional and topical corticosteroid therapy Proliferative and necrotising otitis externa (PNOE) is a very rare disease affecting the ear canals and concave pinnae of kittens. This report describes a 5-month-old cat with PNOE. Histopathological examination confirmed the diagnosis. Treatment was initiated with local injection of methylprednisolone acetate into the lesions. The cat was subsequently treated (...) with clobetasol propionate cream, a potent topical glucocorticoid ointment. The cat showed marked improvement. While topical treatment with tacrolimus, an immunosuppressive agent, is reported to be an effective therapy, to the best of our knowledge, this is the first report to treat PNOE with local corticosteroid therapy.

Full Text available with Trip Pro

2016 The Journal of Veterinary Medical Science

144. A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period (PubMed)

A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period Topical corticosteroids (TCS) are regarded as the mainstay treatment for atopic dermatitis (AD). As AD has a tendency to heal naturally, the long-term efficacy of TCS in AD management should be compared with the outcomes seen in patients with AD not using TCS. However, there are few long-term studies that consider patients with AD not using TCS. We designed a prospective multicenter cohort

Full Text available with Trip Pro

2016 Clinical, cosmetic and investigational dermatology

145. Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. (PubMed)

Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. 25632986 2016 03 23 2015 06 24 1651-2057 95 6 2015 Jul Acta dermato-venereologica Acta Derm. Venereol. Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. 758-9 10.2340/00015555-2057 Nadal Marion M Department of Dermatology, CHRU

Full Text available with Trip Pro

2015 Acta Dermato-Venereologica

146. Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice. (PubMed)

Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice. Topical corticosteroid and calcineurin inhibitor have similar therapeutic benefits in atopic dermatitis (AD), but the differences in therapeutic mechanisms of action of these agents against AD symptoms are not fully understood.This study was performed to examine the different effects of topical betamethasone valerate (BMV), clobetasol propionate (CBP (...) the strongest effect. CBP significantly reduced epidermal thickness compared with Vas and NT. There were no significant differences in the numbers of interleukin-31-immunoreactive cells and mast cells, or in expression of epidermal thymic stromal lymphopoietin among all five groups.The therapeutic potency of TAC against AD-like symptoms, including pruritus, is equal to that of the corticosteroid CBP. Epidermal innervation of sensory nerves itself might not be related to the therapeutic effects of topical

2016 Journal of dermatological science

147. The effects of oral and topical corticosteroid in rabbit corneas. (PubMed)

The effects of oral and topical corticosteroid in rabbit corneas. To determine the most effective route of administration of corticosteroids in the treatment of ocular surface disease, by characterizing the difference between oral prednisolone and topical dexamethasone administration using an animal model.Pharmacokinetic analyses determined the corticosteroid concentrations in the normal ocular tissues of rabbits after oral or topical administration of corticosteroids using LC-MS/MS. In wound (...) observed between orally and topically administered groups. Pharmacokinetic analyses showed that the distribution of dexamethasone after topical administration was superior to that after oral administration in the cornea. In contrast, both concentrations of corticosteroid applied topically and orally were similar with regards to AUCs (area under the concentration-time curve) in the conjunctiva. Although the healing rate was slower in the topical group, all corneas were almost healed within 96 h

Full Text available with Trip Pro

2016 BMC Ophthalmology

148. Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP<sup>®</sup> scale: prevalence, risk factors and the impact of therapeutic patient education. (PubMed)

Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP® scale: prevalence, risk factors and the impact of therapeutic patient education. 27608366 2017 03 15 1468-3083 31 3 2017 Mar Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP ® scale

2016 Journal of the European Academy of Dermatology and Venereology

149. Safety of Topical Corticosteroids in Pregnancy. (PubMed)

Safety of Topical Corticosteroids in Pregnancy. Are topical corticosteroids safe for use in pregnancy?The available evidence found no associations of maternal use of topical corticosteroids of any potency with mode of delivery, birth defects, preterm delivery, fetal death, and low Apgar score. However, maternal use of potent to very potent topical corticosteroids, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very large, is associated with low

2016 JAMA dermatology (Chicago, Ill.)

150. Assessment of "corticophobia" as an indicator of non-adherence to topical corticosteroids: A pilot study. (PubMed)

Assessment of "corticophobia" as an indicator of non-adherence to topical corticosteroids: A pilot study. Concerns regarding topical corticosteroid (TCS) use, broadly known as "corticophobia", are highly prevalent among dermatology patients and often result in non-adherence to TCS. This non-adherence contributes to poor disease control and increased health care costs. However, it is unknown if assessment of these concerns might help to identify patients at risk of TCS-non-adherence. Clinical (...) tools indicating non-adherence could be helpful to improve management of this patient group.To assess whether the available tools for measuring concerns regarding corticosteroids, the TOPICOP scale and the 0-10 Visual Analogue Scale (VAS), could help to detect non-adherence to TCS.In 75 patients with concerns regarding TCS use both the TOPICOP scale and VAS were anonymously assessed. A comparison was made between TCS-adherent and non-adherent patients regarding the intensity and characteristics

2016 Journal of Dermatological Treatment

151. Evaluation of the influence of pharmacists and GPs on patient perceptions of long-term topical corticosteroid use. (PubMed)

Evaluation of the influence of pharmacists and GPs on patient perceptions of long-term topical corticosteroid use. To assess pharmacist and general practitioner (GP) advice and behaviors, as related to and reported by patients and parents of patients using topical corticosteroids (TCS) on a long-term basis.Multicenter cross-sectional survey of patients (aged 18+) and parents of pediatric patients (aged <18) with a history of long-term (≥1 month) TCS use, assessing: TCS treatment adherence

2016 Journal of Dermatological Treatment

152. Descemet's Membrane Endothelial Keratoplasty: Risk of Immunologic Rejection Episodes after Discontinuing Topical Corticosteroids. (PubMed)

Descemet's Membrane Endothelial Keratoplasty: Risk of Immunologic Rejection Episodes after Discontinuing Topical Corticosteroids. To assess the risk of immunologic rejection episodes if topical corticosteroids are discontinued 1 year after Descemet's membrane endothelial keratoplasty (DMEK) compared with continued once-per-day use.Prospective, longitudinal, parallel-group study.A total of 400 eyes of 259 DMEK recipients, aged 23 to 90 years.Patients were enrolled 1 year after DMEK and allowed (...) to choose whether to stop or continue once-daily topical corticosteroids to maximize compliance. Fellow eyes were eligible for enrollment because the donor grafts were independent. Participants were examined at 1, 3, 6, and 12 months during the second year after DMEK. Results were assessed using Kaplan-Meier survival analysis.Incidence of immunologic rejection episodes.Steroids were discontinued in 277 eyes (no steroid group) and continued once per day in 123 eyes (steroid group). The subject

2016 Ophthalmology

153. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. (PubMed)

Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. Ingenol mebutate (IngMeb) is approved for treatment of actinic keratoses (AK) and may cause unpredictable local skin responses (LSR).We sought to investigate whether IngMeb-induced LSR, pain, and pruritus could be alleviated with a topical glucocorticoid and, further, to assess efficacy, cosmetic outcome, and patient (...) satisfaction in patients with severe photodamage.In this blinded, randomized controlled clinical trial, patients with multiple AK and field cancerization of the face or scalp were treated in 2 areas with IngMeb (0.015%) daily for 3 days. After finalized IngMeb treatment, 1 area was randomized to receive topical clobetasol propionate (0.05%) twice daily for 4 days. Assessments included LSR (0-24; days 1, 4, 8, 15, 57), pain (0-10) and pruritus (0-3; days 1-15), AK clearance (days 15, 57), and cosmetic

2016 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

154. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. (PubMed)

Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Atopic eczema is a chronic inflammatory disease affecting about 30% of Australian and New Zealand children. Severe eczema costs over AUD 6000/year per child in direct medical, hospital and treatment costs as well as time off work for caregivers and untold distress for the family unit. In addition, it has a negative impact on a child's sleep, education, development and self-esteem. The treatment (...) of atopic eczema is complex and multifaceted but a core component of therapy is to manage the inflammation with topical corticosteroids (TCS). Despite this, TCS are often underutilised by many parents due to corticosteroid phobia and unfounded concerns about their adverse effects. This has led to extended and unnecessary exacerbations of eczema for children. Contrary to popular perceptions, (TCS) use in paediatric eczema does not cause atrophy, hypopigmentation, hypertrichosis, osteoporosis, purpura

Full Text available with Trip Pro

2015 Australasian Journal of Dermatology

155. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. (PubMed)

Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Topical corticosteroids are used frequently in dermatology and atopic dermatitis without significant adverse effects. Though ocular diseases such as glaucoma and cataracts are known complications of systemic corticosteroids, the role of topical corticosteroids is limited to case reports. This review assesses the literature regarding topical steroids and their role in ocular diseases. There is evidence of harm (...) to vision when potent topical corticosteroids are inappropriately used for prolonged periods to periorbital sites. There is no evidence to date that weak TCS to the face or potent TCS to areas other than the eyes results in ocular complications. Further research trials are required in this area. © 2015 The Australasian College of Dermatologists.

2015 Australasian Journal of Dermatology

156. Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation (...) of Fluid Retention Due to Superpotent Topical Corticosteroid (RECOPB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02360202 Recruitment Status : Recruiting First Posted : February 10, 2015 Last Update Posted : August 30

2015 Clinical Trials

157. Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue

Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02398539 Recruitment Status : Unknown Verified May 2015 by Eloise Lemon, Akron Children's Hospital. Recruitment status was: Recruiting First Posted : March 25

2015 Clinical Trials

158. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. (PubMed)

Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. There is no consensus regarding the effects on growth velocity of intranasal topical corticosteroid (ITC) use in children. The objective of this study was to determine whether ITC use reduces growth velocity in children with allergic rhinitis (AR).A literature search of the National Center for Biotechnology Information PubMed, EMBASE, SCOPUS, and Cochrane databases from January 1, 1988 to October 7, 2013

2015 International forum of allergy & rhinology

159. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. (PubMed)

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. Severe chronic hand eczema (sCHE) is a persistent, disfiguring disease that responds poorly to conventional treatment and causes substantial physical and psychological disability. The objective of this study was to evaluate efficacy and safety of oral alitretinoin in sCHE (...) in a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing alitretinoin with placebo. Efficacy was assessed every 4 weeks during treatment and 4 weeks after end of treatment (EOT, 24 weeks); responders were assessed every 4 weeks for a further 48 weeks after EOT. The study was conducted at academic and private dermatology centers. The participants were 596 patients with sCHE refractory to potent topical corticosteroids. Patients were treated with daily oral

2015 Journal of drugs in dermatology : JDD Controlled trial quality: predicted high

160. Topical Corticosteroid App

Topical Corticosteroid App Topical Corticosteroid App - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical Corticosteroid App The safety and scientific validity of this study is the responsibility (...) the effectiveness of a mobile application to assist in the prescription of topical corticosteroids (TCS), focusing on best fit choices of potency, vehicle and volume. The mobile application will be developed from the results obtained in a systematic literature review and quality assessment of clinical practice guidelines for topical corticosteroid use. The quality of the guidelines will be assessed using the AGREE II tool. After the app user enters in information concerning patients' rash location and desired

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>